Skip to content
Audio Journal of Oncology 13.2, February 2005

Audio Journal of Oncology 13.2, February 2005

Get the podcast

Reporting from: – Annual Meeting of the American Society of Hematology, December 4-7, 2004, San Diego – Chemotherapy Foundation Symposium, November 10-13 2004, New York – European So

The Audio Journal of Oncology

Reporting from:
– Annual Meeting of the American Society of Hematology, December 4-7, 2004, San Diego
– Chemotherapy Foundation Symposium, November 10-13 2004, New York
– European Society for Medical Oncology Congress, October 29-November 2, 2004, Vienna
– Journal of Clinical Oncology
– New England Journal of Medicine

In this edition:

At the ASH conference in San Diego, Owen O’Connor described his investigation involving heavily pretreated patients with mantle cell lymphoma whose disease responded to bortezomib. George Canellos discussed the clinical implications.

Rituximab-CHOP combination therapy markedly improved outcomes for low-risk, younger patients with diffuse large B-cell lymphoma, according to study results announced by Michael Pfreundschuh.

The oral 5-FU pro-drug capecitabine has performed as well as intravenous therapy, according to Chris Twelves, who presented findings to the Chemotherapy Foundation in New York.

The older drug hydroxyurea was just as effective and caused fewer complications than its molecularly targeted modern replacement, anagrelide, for treating patients with essential thrombocythemia, according to Tony Green,who spoke in San Diego.

Click here for more.

Next in ESMO

All 51 interviews

Interview 51 of 51

Audio Journal of Oncology 13.1, January 2005

Audio Journal of Oncology 13.1, January 2005

Reporting from: – European Society for Medical Oncology Congress, October 29-November 10, 2004, Vienna – Journal of Clinical Oncology – New England Journal of Medicine – Lancet

8 January 2005

Related Episodes

Jacob Sands MD; ESMO 2026: Tarlatamab Bispecific Antibody Maintenance Therapy Prolongs Life for Patients with Extensive Stage Small Cell Lung Cancer

Jacob Sands MD; ESMO 2026: Tarlatamab Bispecific Antibody Maintenance Therapy Prolongs Life for Patients with Extensive Stage Small Cell Lung Cancer

MADRID, Spain—Patients with extensive stage small cell lung cancer now have the green-light to add treatment with the bispecific antibody tarlatamab to their maintenance anti-PD-1 immunotherapy after first line chemo-immunotherapy induction. Results from the phase 3 DeLLphi-305 trial were reported at the 2026 Annual Congress of the European Society for Medical Oncology showing significantly improved overall and progression-free survival. Peter Goodwin spoke with study author Jacob Sands MD, Associate Chief of the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute, in Boston, USA, and Assistant Professor of Medicine at Harvard Medical School:

12 Nov 2026
4 min
Rebecca Dent MD; ESMO 2026: Dato-DXd Brings Dramatic CNS Responses to Patients with Brain Metastases from Resected Inoperable or Metastatic Triple Negative Breast Cancer

Rebecca Dent MD; ESMO 2026: Dato-DXd Brings Dramatic CNS Responses to Patients with Brain Metastases from Resected Inoperable or Metastatic Triple Negative Breast Cancer

MADRID, Spain—The antibody-drug conjugate datopotamab deruxtecan (aTrop-2-directed antibody carrying a topoisomerase inhibitor payload) achieved clinically meaningful intracranial responses among patients with resected inoperable or metastatic triple negative breast cancer with CNS involvement in the TROPION-Breast02 study discussed at the 2026 Annual Meeting of the European Society for Medical Oncology. Peter Goodwin heard the details from the study’s first author: Rebecca Dent MD, Senior Consultant Medical Oncologist and Deputy Chief Executive Officer at the National Cancer Centre in Singapore.

5 Nov 2026
10 min
James Larkin PhD FRCP F Med Sci, ESMO 2026: Personalized mRNA Cancer Vaccines: Melanoma Study Success Provides Proof of Principle for Other Malignancies

James Larkin PhD FRCP F Med Sci, ESMO 2026: Personalized mRNA Cancer Vaccines: Melanoma Study Success Provides Proof of Principle for Other Malignancies

MADRID, Spain— Personalized mRNA cancer vaccines for a range of tumor types are now seen as a realistic possibility thanks to mRNA technology already harnessed for treating melanoma in the phase III INTerpath-001 trial reported at the 2026 Annual Congress of the European Society for Medical Oncology. Peter Goodwin heard the latest on the potential of cancer vaccines from Scientific Co-Chair of ESMO 2026, James Larkin PhD FRCP F Med Sci, Head of The Royal Marsden Skin Unit, and Joint Training Programme Director for Medical Oncology and Lead of the Cancer Immunotherapy Theme at The Royal Marsden’s Institute of Cancer Research NIHR Biomedical Research Centre, in London UK.

2 Nov 2026
15 min